BIOMARIN PHARMACEUTICAL INC
Company Stats
- Market Cap
- $11.6B
- as of Sep 30, 2026
- Enterprise Value
- $10.9B
- Shares Outstanding
- 193.6M
- Free Float
- 98.9%
Income Statement
- Revenue
- $3.2B
- Operating Income
- $409.5M
- Net Income
- $348.9M
- EBITDA
- $489.0M
- Non-cash Impairment
- $125.0M
- Revenue Growth, 3Y
- 15.4%
- FCF Margin, 3Y Avg
- 14.1%
- FCF Margin, Worst Year
- 2.6%
Cash Flow
- Free Cash Flow
- $725.0M
- FCF Yield
- 6.2%
- Owner FCF Yield
- 4.7%
Balance Sheet
- Cash & Equivalents
- $1.3B
- Total Debt
- $600.0M
- Net Cash
- $711.7M
- EV / EBITDA
- 22.29x
Returns & Capital
- SBC, 3Y Avg
- $196.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $3.2B | $725.0M | 22.5% |
| FY2024 | $2.9B | $487.4M | 17.1% |
| FY2023 | $2.4B | $62.6M | 2.6% |
| FY2022 | $2.1B | $54.9M | 2.6% |
| FY2021 | $1.8B | $209.0M | 11.3% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 9, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
BioMarin to Buy Alesta Therapeutics in $275 Million Cash Deal
Healthcare Earnings: Demand Surges, Costs Bite Back